New targeted therapy approved for early-stage HER2-positive breast cancer

https://www.facingourrisk.org/XRAY/Kadcyla-early-stage-HER2-breast-cancer

Full article: https://www.nejm.org/doi/full/10.1056/NEJMoa1814017

The KATHERINE trial looked at the benefit of the new drug, Kadcyla, for treating early-stage breast cancer after surgery and chemotherapy. The results of this study led to FDA approval in May 2019. (6/17/19)

Questions To Ask Your Health Care Provider

Is my breast cancer HER2-positive?
Is a HER2-therapy appropriate for treating my breast cancer?
If I have HER2-positive breast cancer, which therapy is best for me?
What are the risks and benefits of using a HER2-based therapy after surgery?

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.